Skip to main content

BioAegis says its 'inflammation regulator' is best weapon to fight Covid-19

BioAegis Therapeutics is currently awaiting FDA approval to begin testing its plasma gelsolin therapy on Covid-19 patients. The company says its treatment prevents the damage caused by excess inflammation without suppressing the immune system and offers the best defense against the virus.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.